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Among a wide range of cytokines, the Interleukin 12 (IL-12) family has its 
unique structural, functional, and immunological characteristics that have made this 
family as important immunological playmakers. Because of the importance of IL-12 
heterodimeric cytokines in microbial infections, autoimmune diseases, and cancers, 
the authors of this literature discuss about the general characteristics of IL-12 family 
members, the interactions between IL-12 cytokines and pathogenic microorgan-
isms, the interleukins receptors and their strategies for selecting different signalling 
pathways. IL-12 and IL-23 are similar in p40 subunits and both are involved in pro- 
infl ammatory responses while, IL-27 and IL-35 contribute to anti-infl ammatory 
 activities; however, IL-27 is also involved in pro-infl ammatory responses. There are 
some similarities and dissimilarities among IL-12 family members which make 
them a unique bridge between innate and adaptive immune systems. The bioactivi-
ties of IL-12 family indicate a brilliant promise for their applications in differ-
ent fi elds of medicine. The members of IL-12 family are candidate for several thera-
peutics including gene therapy, cancer therapy, tumour therapy, and vaccination. 
To have an accurate diagnostic technique and defi nite treatment regarding to infec-
tious diseases, the playmakers of IL-12 family as effective criteria together with 
microarray technology are the best choices for current and future applications.
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Introduction
The term Cytokine is composed of Cyt/o (Cell) and Kin/e (movement) [1]. 
This term involves a wide range of soluble components such as glycoproteins of 
monokines, lymphokines, interferon-γ (IFN-γ) and interleukins (ILs) which are 
produced via a vast number of cell types. The secreted proteins of cytokines 
 affect their targets throughout different immunological pathways comprised 
of apoptosis (programmed cell death/cell suicide), growth, development and dif-
ferentiation. The activities of cytokines are directly infl uenced by a series of 
regulators and feedbacks. The nonstructural proteins of cytokines are catego-
rized in accordance with their biological functions. The majority of cytokines are 
secreted when an infection/disease is trying to invade the human host and im-
mune system. Therefore, cytokines are recognized as the body’s feedback against 
strangers and stresses [2–7].
According to previous surveys, ILs involve a vast range of structures, func-
tions and diversity to have a considerable role in modulating human immune 
system responses against undesirable conditions such as infectious diseases, 
 autoimmune diseases and cancers. As a duty, ILs contribute to the processes of 
differentiation, growth, progression and production of immune cells for pro-
tecting host body’s from strangers like pathogenic microorganisms including 
bacteria, fungi, protozoa, helminths and viruses. Besides, the anti-infl ammatory 
and pro-infl ammatory activities, allergic reactivities, induction of different types 
of immune regulations and secretions within the immune cells’ system are dom-
inated by ILs. The aforementioned characteristics relating to ILs indicate that, 
they are capable to infl uence different generations and types of immune system 
cells as a powerful defence system against pathogens. The incredible occurrence 
is that, cytokines are able to distinguish microbial microfl ora from the other 
 pathogens. These advanced abilities of ILs, represent them as invaluable biologi-
cal playmakers within the human immune system. There are over than 40 types 
of ILs with different properties. The IL-12 family members are known as quite 
distinct cytokines rather than others; because of their unique characteristics of 
heterodimeric structures [3, 8–13].
The processes of secretion, resolution, activation and termination of cy-
tokines including IL-12 family members are directly in association with tran-
scriptional, post-transcriptional, translational and post-translational factors. 
These factors determine and programme different regulons including transcrip-
tional, post-transcriptional, translational and post-translational regulons. The 
transcriptional regulons trigger genes to express mRNA molecules encoding dif-
ferent immunofunctional proteins. So, the process of gene expression regulation 
is known as transcription. The expression of cytokines such as IL-12 family 
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members is performed throughout the process of DNA molecules conversion 
 into mRNAs. This process is followed by another step that is considered as a very 
fi ne regulated procedure in which the hidden data within mRNA molecules are 
translated into a vast range of immunological responses such as cytokines secre-
tion. Thus, the transcription phase involves processed mRNAs encompassing 
caps and polyadenylated tails. It must be considered that, the mRNA molecules 
are increased in parallel with cytokines secretion [14–16].
There are some important approaches which control the process of mRNA 
translation. The presence, and absence of mRNAs and the translation inhibition 
of mRNA molecules are regarded as particular factors which determine and pro-
gramme post-transcriptional regulons. So, the post-transcriptional components 
dominate the process of genes expressions which are relating to immunological 
reactions. In other word, the post-transcriptional pathway regulates the running 
mRNA molecules from nucleus, localization of mRNAs within cellular cyto-
plasm, the beginning of translation step and disappearance of mRNAs [15–18].
According to recent investigations, initiation and termination of immuno-
logical reactions including expression of anti-infl ammatory and pro-infl amma-
tory ILs like IL-12 family members are also regulated by transcription and post-
transcription processes. The beginning and termination of cytokines secretion 
may lead to occurrence of serious damages within tissues. So, aforementioned 
processes are achieved in a quick and fast duration. Today, our knowledge about 
mRNAs and the related processes has risen up via advanced molecular technol-
ogy of microarray. This reliable, reproducible, rapid and accurate technique is 
effective for detecting and identifying DNA and RNA molecules [19–22].
Because of the noticeable properties of IL-12 family members against in-
fectious diseases as important immunological playmakers regarding to human 
immune system, the main aspect of the present review literature is to focus on 
characteristics of the family members of IL-12.
IL-12 family members
The IL-12 family members are consisted of IL-12, IL-23, IL-27, and IL-35. 
They contribute to regulation of immune system against infectious diseases, au-
toimmune diseases and cancers. The main sources of triad ILs involving IL-27, 
IL-23 and IL-12 are active antigen presenting cells (APCs) while the IL-35 is 
produced by activated and resting regulatory T (Treg) cells including thymus 
originated Tregs (natural Treg (nTreg) cells) and the peripheral induced Treg 
(iTreg) cells in high level and IL-35-producing regulatory B (Breg) cells in low 
level. The quadruple group of IL-12 family converts the immature CD4+ T cells 
4 BEHZADI et al.
Acta Microbiologica et Immunologica Hungarica 63, 2016
into memory T cells and T helper (Th) cells in which the innate part of defence 
system links into the adaptive immunity. Actually, some IL-12 cytokines such as 
IL-12 and IL-23 are the main stimulators for memory T cells proliferation. How-
ever, IL-12 cytokines normally infl uence the duration of effectors responses. Be-
sides, these cytokines are able to polarize the innate or native T cells [23–31].
The members of IL-12 are all involved in cytological and physiological 
activities in association with CD4+ Th cells. Indeed, naїve Th cells are able to be 
differentiated into four major categories of Th1 (producing IFN-γ), Th2 (produc-
ing IL-4, IL-5, and IL-13), Th17 (producing IL-17A, IL-17F, IL-21, and IL-22, 
IL-26) and Treg (producing transforming growth factor (TGF)-β, IL-10, and 
 IL-35) (Fig. 1). IL-12 and IL-23 are necessary cytokines for Th1 and Th17 cells 
activities [12, 32–35].
The fourfold members of IL-12 family have some similarities and dissimi-
larities in their structures and functions. Each member of IL-12 family is indi-
vidually discussed below:
Figure 1. Naїve T cell differentiation into four types of Th cells 
and their related cytokine secretions. The naїve Th cells are able to be induced and make several Th 
cell subsets. IL-12 and IL-27 activities result in induction of INF-γ producing Th1 cells. 
The Th1 cells are known as mediators of cellular immune system. IL-14 is Th2 cells inducer. 
The triggered humoral immune system mediator of Th2, is able to produce ILs-4, 5, 
and 13. 5 ILs including IL-1, IL-6+TGF-β, IL-21, and IL-23 are important inducers of Th17 cells. 
It must be mentioned that IL-23 is known as a Th17 stabilizer rather than Th17 inducer. The Th17 cells 
are able to produce a wide range of ILs including IL-17A, IL-17-F, IL-21, IL-22, and IL-26.
TGF-β and IL-35 are Treg inducers. However, IL-35 is also known as a Treg production
 IL-12 FAMILY CYTOKINES 5
Acta Microbiologica et Immunologica Hungarica 63, 2016
IL-12 and general characteristics
Trinchieri [82] and Gately et al. [70] are the fi rst scientists that discovered 
cytokine of IL-12. IL-12 is known as one the most signifi cant cytokines that 
regulates immune system responses. The 70 kDa pro-infl ammatory molecule of 
IL-12 works as a powerful response to pathogenic microorganisms. B cells, den-
dritic cells (DCs) and macrophages (MΦs) are the main resources for IL-12 cy-
tokine. Structurally, IL-12 is consisted of two subunits of α (IL-12p35) and β 
(IL-12p40) weighting 35 kDa and 40 kDa, respectively (Fig. 2). The α-spiral 
structure subunit resembles IL-6 and the β is similar to IL-6 receptor. Each subu-
nit is produced by a separate chromosome and the subunits are linked via cova-
lent bonds [36–38].
According to the recent studies, IL-12 α-subunits are produced in differ-
ent type of cells but in low level. On the other hand, the β-subunits are secreted 
only within limited cells that are able to produce IL-12p70 including activated 
DCs, MΦs, monocytes and neutrophils. Hence, to form an active IL-12 cytokine; 
there is a need for simultaneous co-expression of IL-12p35, IL-12p40, and 
 IL-12p70 within a same home cell. The level of IL-12p40 is up to 1000 rather than 
IL-12p35. So, always there is a high amount of unbound and free molecules of 
IL-12p40 within the cells [39–41].
Figure 2. The structures of IL-12 family, related receptors and signalling pathway in an immune cell. 
The IL-12 family is consisted of IL-12, IL-23, IL-27 and IL-35. The IL-12 (p35/p40) sends signals 
through its receptor (IL-12R-β1/IL-12R-β2), TYK2/JAK2, and STAT4 molecules.
The IL-23 (p19/p40) utilizes its receptor (IL-12R-β1/IL-23R) for sending signals through TYK2/JAK2, 
and STAT3/STAT4 signalling pathway.
The IL-27 (p28/Ebi3) and the related receptor (gp130/IL-27R (WSX-1)) use JAK1/JAK2, 
and STAT1/STAT3 molecules as a regular signalling pathway for signal casting.
IL-35 (p35/Ebi3) possesses four different receptors (gp130/IL-12R-β2 (heterodimers)), gp130/gp130 
(homodimers), IL-12R-β2/IL-12R-β2 (homodimers), and IL-27R (WSX-1)/IL-12R-β2 (heterodimers). 
The fi rst three receptors apply JAK1/JAK2, and STAT1/STAT4 and the last receptor uses JAK1/JAK2, 
and STAT1/STAT3 as appropriate signalling pathways for moving the subjected signals.
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Recent studies decipher the transcriptional and post-transcriptional regu-
lations regarding to IL-12 family members. The combination of myeloid dif-
ferentiation primary response gene 88 (MyD88) with toll-like receptors (TLRs) 
(excluding TLR3) activates nuclear factor-κB (NF-κB). On the other hand, the 
simultaneous presence of IFN-Regulatory factor 5 (IRF5) with MyD88 and NF-
κB provides IL-12 family members producing genes to express [42–44].
The contribution of TLR ligands prepares an appropriate situation for 
 transcriptional regulations. Hence lipopolysaccharide (LPS), a bacterial TLR li-
gand is able to rearrange the confi guration of a particular region (nucleosome-1) 
relating to p40 gene promoter. The new arrangement of the region is prompt for 
activation of several transcription factors including CCAAT/enhancer binding 
protein (C/EBP). NF-κB is an essential factor for activating promoter during 
the presence of LPS. The consensus region of NF-κB, ETS links ETS-2 to PU.1 
to make them ready for creating a complex with some other components such as 
c-Rel, some of IFR members, and IFN-consensus sequence binding protein 
(ICSB). The basis of transcriptional and translational processes of p35 and p40 
genes expressions is the same with some differences in details; however, a main 
functional dissimilarity is distinguished regarding to p35 and p40 genes expres-
sions. The common enzyme of extracellular signal regulated kinase mitogen 
 activated protein kinase (ERKMAPK) between p35 and p40 genes expressions 
processes acts with different attitudes. ERKMAPK is known as a halter in p40 
gene expression but as a restrictive agent in p35 gene expression [45–47].
The processes of post-transcriptional and post-translational in associa-
tion with p35 and p40 occur within the cell milieu but in different pathways. The 
cleavage of p40 is performed once during the entrance into the endoplasmic 
 reticulum (ER), while the p35 is cleaved twice within the ER milieu. The tran-
scriptional, post-transcriptional, and post-translational processes pertaining to 
the other IL-12 family members subunits are as the same with some dissimilar-
ity in details [48–50].
IL-12 and pathogenic microorganisms
Several surveys show a high induction of IL-12 in the presence of micro-
bial agents such as bacteria (Gram positive and Gram negative), fungi, helminths, 
protozoa, and viruses. The microbial components act as TLR ligands. The signal-
ling process between microbial components and their related TLRs leads to in-
duction of IL-12 via innate immune system. TLRs are recognized as important 
balancers for secretion of IL-12 family members. Bacterial pieces like DNA, 
LPS, peptidoglycan and lipoteichoic acid are important inducers of IL-12. The 
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adaptive system encompasses to produce IL-12 via CD40 and APCs attachments 
which are mediated by T cells CD40L receptors [42, 51–59].
There is a two-way positive interaction between IL-12 and IFN-γ. The se-
cretion of IL-12 leads to production of IFN-γ by Natural killer (NK) and T cells. 
The axis of IL-12/IFN-γ regulates immunological reactions. Moreover, IL-12 
 increases the cytotoxicity of cytotoxic T and NK cells and stimulates T cells dif-
ferentiation into Th1 effectors. These characteristics relating to IL-12, support 
the importance of IL-12 in cell mediated pathways within immune system. Si-
multaneously, the secretion and dissemination of IFN-γ triggers the production of 
IL-12; which is an appropriate mechanism against pathogenic microorganisms 
such as Listeria monocytogenes, Mycobacterium tuberculosis, Candida albicans 
and Leishmania major. In other word, IFN-γ activates phagocytes to achieve 
their bactericidal activities throughout the production of more IL-12 and phago-
cytosis. IL-12 is known as an effective biological inhibitor for IL-4, IL-10, IL-11, 
and IL-13 [33, 60–66].
The absence of IL-12 predisposes human cells for invasion of intra-MΦ 
pathogenic microorganisms such as Francisella tularensis, Klebsiella pneumo-
niae, Mycobacteria, and Salmonella. Stimulation of TLR3 (viral ligands), TLR4 
(bacterial (Gram negative bacteria) ligands) and TLR8 (viral ligands) gives rise to 
induction of IL-12p35. Stimulation of aforementioned TLRs and TLR2 (fungal 
and bacterial (Gram positive) ligands) induces IL-12p40 subunit [52, 67–69].
IL-12 receptors and signalling pathway
IL-12 affects the immune system activities throughout binding to IL-12 
receptors (IL-12Rs). The IL-12R is composed of two subunits of β1 and β2 which 
their genes are situated on two different chromosomes. The β1 links to IL-12p40 
and the β2 binds to IL-12p35 (Fig. 2). The role of β2-subunit is to convert signals 
received from IL-12. The highest affi nity between IL-12 and IL-12R is performed 
when all the IL-12 and IL-12R subunits are actively present [12, 70].
Each subunit of IL-12R has its distinct biological activity. The cytoplas-
mic end of IL-12R-β1which is missing the three tyrosine amino acids within 
 intracellular domain, is bound to Tyrosine kinase-2 (TYK2). The mammalian 
Janus kinases (JAKs) involve four members including JAK1, JAK2, JAK3 and 
TYK2. The lack of tyrosine residues within IL-12R-β1 subunit prevents the con-
tribution of β1-subunit in the process of signal transducing. The key role of IL-
12R-β1 is contributing in ligand binding process. In contrast, the IL-12R-β2 
which binds to JAK-2 contributes in signalling transduction process throughout 
the three amino acid residues of tyrosine. These tyrosine amino acids are recog-
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nized as a suitable binding site for signalling and triggering transcription 4 
(STAT4) (Fig. 2). So, the activation of signalling pathway of JAK-STAT is done 
via IL-12R induction. Several investigations indicate that, signals activate related 
JAK(s) which may lead to phosphorylate the attached STAT molecule(s). Follow-
ing the phosphorylation process of STAT molecule(s), DNA binding, nuclear 
movement, and dimerization will happen. It is revealed that not only IL-12 but 
also the majority of cytokines use JAK-STAT pathway to transmit related signals. 
A huge amount of signals sent from more than 50 cytokines are transmitted via 
seven molecules of STAT (STAT6, STAT5b, STAT5a, STAT4, STAT3, STAT2, 
and STAT1) among mammals. IL-12 is in association with STAT1, STAT3, 
STAT4, STAT5a and STAT5b. The STAT4 has the most important role in IL-12 
signalling pathway. The induction of STAT4 by IL-12 may lead to promotion of 
IFN-γ production. Indeed, IL-12 by triggering the expression of T-bet provides 
the Th1 responds and IFN-γ secretion [36, 71–82].
Different studies show the amazing property of plasticity among Th17 
cells. This characterization is appeared by some changes within transcription 
factors genes which produce Foxp3, ROR-γ-t, and T-bet. Th17 cells are able to be 
converted into Tregs or other types of Th1 cells and vice versa. This process is 
mediated by the transcription factor of ROR-γ-t which is known as an impor-
tant regulator agent in association with Th17 cells. Th17 cells have positive infl u-
ences on Th1 cells differentiation through IL-17 secretion. The IL-17 affects di-
rectly on DCs, which results in IL-12 upregulation. This process is applied 
regarding to intracellular bacterial agents like F. tularensis (the causative agent 
of tularaemia). The activation of STAT4 molecule by IL-12 may lead to genera-
tion of Th1 cells. The increase of Th1 cells results in considerable secretion of 
IFN-γ. An increase in Th1 secretions can cause infl ammation symptoms within 
a wide range of autoimmune diseases. On the other hand, Th1 cells have antago-
nistic manner against Th17 cells which may lead to suppression of these cells. 
The IL-12 plays a key role for polarizing and stabilizing Th1 phenotype against 
intracellular pathogenic infectious agents and the related autoimmune diseases 
[12, 34, 41, 69, 82–87].
IL-23 and general characteristics
Ten years after identifi cation of IL-12, IL-23 as the second member of 
 IL-12 family was identifi ed in 2003. Resembling to IL-12, IL-23 is a cytokine that 
mediates pro-infl ammatory mechanism. IL-23 is composed of two subunits in-
cluding IL-23p40 (as the same in IL-12) and IL-23p19. The co-production of both 
subunits involving IL-23p40 and IL-23p19 within a same cell and at the same 
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time leads to appearance of disulfi de bonds between the subunits and the start of 
normal bioactivity of IL-23 (Fig. 2). There is a 40 percentage similarity between 
IL-23p19 and IL-12p35 sequences [38, 39, 88–91].
The main IL-23 secreting cells are recognized as activated skin and mu-
cosa membranes APCs such as B cells, endothelial cells, MΦs, monocytes and 
DCs against pathogenic microorganisms. The main known key roles for IL-23 
are: triggering IL-17 (responsible for bone erosion and tissue malignancies) via 
Th17 cells, IL-22, and the development of memory T cells. Secretion of IFN-γ 
(by T cells and NK cells), and differentiation of Th1 with low rates are known 
as circumstantial role for IL-23. The intensive communication between CD40 
and CD40L, may lead to increase the production of IL-23, induction of IL-23R 
expression, and a positive circular circumstance for promoting IL-23 produc-
tion. Fungal elements trigger for IL-23 secretion which this occurrence causes 
differentiation among Th17 cells [35, 92–99].
Recent researches indicate that, the presence of IL-23 guarantees the secre-
tion and survival of Th17 cells [32].
IL-23 and pathogenic microorganisms
Similar to IL-12, stimulation of TLR2, TLR3, TLR4 and TLR8 via patho-
genic microbial ligands triggers the simultaneous secretion of IL-23p40 and 
 IL-23p19. The stimulation of TLR2 via Gram positive bacteria peptidoglycan is 
signifi cantly more effective than TLR4 via Gram negative bacteria LPS for expres-
sion of IL-23p19 and secretion of IL-23. The virulence factor of pertussis toxin 
produced by Bordetella pertussis promotes the secretion of IL-23. Many studies 
indicate that the both forms of dimorphic opportunistic fungus of C. albicans 
including yeasts and hyphae trigger the secretion of IL-23 via stimulation of 
 Dectin-1, TLR4, and TLR2 (by yeast) or TLR2 and Dectin-2 (by hyphae) [68, 87, 
100–104].
It is revealed that, microbial components and threatening signals within the 
human body stimulate the secretion of IL-23 throughout the exposed MΦs, 
monocytes, and DCs in a few hours. In consequence, IL-17 is produced and other 
cells are activated in a cascade pathway which fi nally may lead to pro-infl amma-
tion within infected or wounded anatomical site. The chronic bowel infl amma-
tion of Crohn’s disease (CD) is an autoimmune disorder in association with IL-23. 
Thus, IL-12 and IL-23 are recognized as acute protectors for immune system 
surveillance. Besides, the importance of IL-23 is identifi ed during lung infec-
tions caused by Mycobacteria, K. pneumoniae, candidemia caused by C. albicans, 
and salmonellosis caused by Salmonella. The axes of IL-23-IFN-γ and IL-23-IL-17 
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are the most effective pathways against extracellular opportunistic pathogenic 
microorganisms such as C. albicans (causative agent of different types of can-
didiasis), Pseudomonas aeruginosa (causative agent of wounds and urinary tract 
infections (UTIs), etc.), Escherichia coli (causative agent of different infections 
like UTIs) K. pneumoniae (causative agent of lungs, wounds and UT infections) 
and etc. [34, 38, 63, 64, 87, 105–113].
Furthermore, recent researches reveal that the colonization of normal fl ora 
and useful intestinal microbiota in human alimentary tract prevents the attach-
ment of pathogenic microorganisms and balances the immunological responses. 
The intestinal microbiota increases production of IL-23 which may lead to induce 
Th17 cells for secreting IL-17. Therefore, the presence of commensal bacteria 
protects intestinal milieu against pathogenic microbial agents throughout IL-23/
Th17 axis. Interestingly, the high increase of Th17 cells within intestines triggers 
epithelial cells to produce IL-25. IL-25, reduces IL-23 secretion, downregulates 
the expansion of Th17 cells and rebalances the intestinal homeostasis [95, 114, 
115].
Investigations show that microbial productions are the major triggering 
factors which may lead to secret IL-12 and IL-23 via immunological innate cells 
system. IL-12 prevents the production of IL-23 [47, 50, 116].
Previous investigations indicate that, IL-23 is not necessary for differenti-
ating Th17 cells. However, the presence of IL-23 is vital for polarization and 
stabilization of Th17 cells which leads to appearance of infl ammation symptoms 
in different types of autoimmune diseases comprising psoriasis, multiple sclero-
sis, rheumatoid arthritis, CD, and Experimental autoimmune encephalomyelitis 
(EAE) etc. Not only IL-23, but also IL-12 has a strong infl ammatory effect on 
autoimmune diseases with different pathways [12, 39, 69, 83, 84, 87, 89, 117, 118].
IL-23 receptors and signalling pathway
IL-23 possesses a bi-subunit receptor consisted of IL-12R-β1 (pairing with 
IL-23p40) and IL-23R (matching with IL-23p19). The presence of all subunits 
regarding to IL-23 and its receptor guarantees the occurrence of high affi nity 
bonds. The biological effects of IL-23 are performed via heterodimeric signalling 
pathways of JAK2, STAT3, STAT4, and TYK2 (Fig. 2). Surveys show that IL-6 
and IL-21 are the main cytokines which control the regulation of IL-23R [4, 88, 
89, 118, 119].
After linking between IL-23 subunits including IL-23p40 and IL-23p19 
and their receptors, the STAT3 and STAT4 will be activated (Fig. 2). In parallel 
with polarization of Th17 cells, IL-23 supports the promotion of heterodimeriza-
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tion of STAT3 and STAT4. Active STAT3 molecules increase the production of 
cytokines regarding to infl ammatory activity. Moreover, STAT3 heterodimers 
trigger the infl ammatory related subset of T cells, Th17. STAT3 is directly affects 
the process of Th17 differentiation [77, 78, 120].
IL-27 and general characteristics
The heterodimeric IL-27 is consisted of two subunits including IL-27p28 
and Epstein-Barr virus induced gene 3 (EBi3). The EBi3 which resembles IL-
12p40 is a glycoprotein with a molecular weight of 34 kDa. The IL-27p28 subunit 
is a helical peptide with a molecular weight of 24.5 kDa. Different surveys show 
that, each subunit is secreted separately and the links between EBi3 and IL-27p28 
are unstable because of the lack of sulphide bonds. Interestingly, EBi subunit is 
able to connect with IL-12p35 to create IL-35 (Fig. 2) [121–124].
APCs (such as DCs, and MΦs) are the main resources that secrete IL-27. 
Two functional key roles including inhibitory and pre-stimulatory have recog-
nized for IL-27. IL-27 is able to inhibit the process of immune system responses 
(in both sections of innate and adaptive immunities) and to limit the progression 
of infl ammatory. Previous investigations indicate that IL-27 operates as a func-
tional antagonist cytokine to suppress T cells activities and responses. The sup-
pressive functional effects of IL-27 on MΦs and neutrophils are identifi ed in in-
fectious sepsis. Cooperation of IL-27 and IL-12 may lead to trigger mast cells, 
monocytes, NK and T cells to secrete the IFN-γ. IFN-γ stimulates the production 
of IL-27 in a positive feedback loop which may lead to suppress the infl amma-
tory responses. Moreover, the presence of IL-2 together with IL-27 prevents the 
proliferation of Th2, Th17 cells and production of IL-12 and IL-23. On the other 
hand, the upregulation of T-bet and intracellular adhesion molecule-1 (ICAM-1) 
gives IL-27 permission for promoting the process of Th1 differentiation. IL-27 in 
the presence of TGF-β is able to produce Type 1 regulatory T (Treg1) cells that 
secrete anti-infl ammatory IL-10. However, for differentiation of Th1 and secre-
tion of IFN-γ, IL-27 plays its pro-infl ammatory role [122, 123, 125–127]. 
IL-27 and pathogenic microorganisms
The anti-infl ammatory characteristic of IL-27 leads to downregulation of 
infl ammatory process in the meanwhile of acute and chronic infections. The in-
duction of IL-10 and direct suppression of Th1, Th2 and Th17 by IL-27, subverts 
the effi cacy of immune responses for the most; in contrast, the presence of anti-
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IL-27R and IL-12 upregulates the pro-infl ammatory responses throughout differ-
ent cytokines such as IL-18, IFN-γ and tumour necrosis factor-α (TNF-α). These 
mechanisms are studies on Mycobacterium tuberculosis, Leishmania major, 
L. donovani, Toxoplasma gondii, Plasmodium berghei, and Trypanosoma cruzi. 
Thus, IL-27 creates a critical condition during infectious diseases for the host 
immune system by preventing secretion of IL-2, IL-6, and IL-17 and subverting 
immune responses against microbial pathogens. The inhibition of IL-2 produc-
tion may happen via suppressor of cytokine signalling 3 (SOCS3) [123, 128–132].
IL-27 receptors and signalling pathway
Similar to IL-12 and IL-23, IL-27 has receptor of IL-27R which is com-
posed of a gp130 subunit and a WSX-1 subunit. The latter belongs to the class I 
cytokine receptor family (TCCR) (Fig. 2). B (activated) cells, DCs, Endothelial 
(activated) cells, mast cells, monocytes, naїve T cells, and NK cells are all recog-
nized as the IL-27R producer cells. The IL-27 JAK-STAT signalling pathway 
varies in different immune cells including mast cells (STAT3), monocytes (NF-
κB, STAT1, and STAT3), naїve T cells (TYK2, JAK1, JAK2, STAT1, STAT2, 
STAT3, STAT4, STAT5a, and STAT5b) and NK cells (JAK1, STAT1, STAT3, 
STAT5a, and STAT5b). STAT1 and STAT3 molecules are needed for IL-27 bio-
logical activities [123, 133–139].
IL-35 and general characteristics
The heterodimeric cytokine of IL-35 involves two subunits of p35 and Ebi3 
which are also seen in IL-12 and IL-27 (Fig. 2). IL-35 is the newest member of 
IL-12 family. IL-12 and IL-23 are pro-infl ammatory cytokines, while IL-27 has 
anti-infl ammatory activities for the most. However, there are some activities 
(such as Th1 promotion and IFN-γ secretion) which are performed by IL-27. 
In the case of IL-35, this cytokine is recognized as a defi nite immunosuppressor 
with a huge potent of suppression. T cells (Th1, Th17) are suppressed via cell 
cycle termination in G1 phase. No apoptosis feature is used within T cell suppres-
sion process. Prior to APCs, nTregs are the main resources for IL-35 secretion. 
IL-35 resembling IL-10 and TGF-β, has the capability of triggering proliferation 
of the iTreg of iTr35 (the CD4+ Tregs induced by IL-35). iTr35 produces IL-10, 
Foxp3, and TGF-β; but suppresses via IL-35. nTregs are able to transform the 
 suppressed T cells into iTr35. The contribution of iTr35 for regulating the envi-
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ronmental parameters regarding to infl ammation is identifi ed. Moreover, the 
 entrance of IL-35 into the infl ammatory sites at the present of nTreg works for the 
maximal potential [8, 12, 13, 28].
IL-35 and pathogenic microorganisms
Immune cells of monocytes which are activated by bacterial LPS and pro-
infl ammatory cytokines are able to transcribe IL-35 genes [9]. More investiga-
tions are needed relating to IL-35 activities against microbial pathogens.
IL-35 receptors and signalling pathway
Unlike other members of IL-12 family, IL-35 encompasses four receptors 
including IL-12R-β2-IL-27R (WSX-1), IL-12R-β2-IL-12R-β2, IL-12R-β2-gp130, 
and gp130-gp130. Normally, IL-12R-β2 subunit is produced within active NK 
and T cells; while gp130 is secreted by the majority of immune cells. The IL-35 
signalling pathway is consisted of JAK1, JAK2, STAT1, STAT3, and STAT4 
 molecules (Fig. 2). A group of B cells such as regulatory B cells which produce 
IL-35 possesses two receptor subunits of IL-12R-β2 and IL-27R-α for IL-35 for 
activating STAT1 and STAT3 molecules. This characteristic indicates the prob-
able contribution of regulatory B cells in association with immune system re-
sponses in healthy people and patients. In T cells, the IL-35 signals encompass 
three receptor subunits comprising IL-12R-β2-IL-12R-β2, IL-12R-β2-gp130, and 
gp130-gp130 which activate STAT1 and STAT4 molecules [23, 28, 75, 140, 141].
The connection of IL-12 family with IL-6 family
In addition to IL-12 cytokines, the IL-6 cytokine family belongs to type-I 
cytokines. The IL-12 family members excluding IL-35 (IL-35 is secreted by 
Tregs and some of Bregs) are secreted by APCs (DCs, monocytes, and MΦs), 
whereas the IL-6 cytokines are produced by a vast range of cells including adi-
pocytes, B cells, endothelial cell, fi broblasts, keratinocytes, mesangial cells, 
monocytes and T cells. These families have some similarities and dissimilarities 
regarding to their structural and molecular properties. The IL-12 and IL-6 super-
families encompass similar structural motifs of four-helix-bundle and hemat-
opoietin receptor domain. On the other hand, the IL-6 family members including 
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cardiotrophin-1 (CT-1), cardiotrophin like cytokine (CLC), ciliary neurotrophic 
factor (CNTF), IL-6, IL-11, leukaemia inhibitory factor (LIF), neuropoietin 
(NP), and oncostatin M (OSM) are single-structured monomers while the IL-12 
cytokines possess a heterodimeric structure of α–β-subunits (Table I). Further-
more, the cytokines biological activities are performed via their specifi c recep-
tors. In this article we just focus on IL-6 and its receptors [31, 94, 122, 142–146].
The IL-6 receptors comprising (IL-6R/IL-6R-α/gp80/CD126) and gp130 
(IL-6R-β/CD130) molecules have a key role in association with IL-6 biological 
tasks. The hexamer complex of IL-6-IL-6R-α-gp130 (including six molecules/
two molecules per each) creates powerful signals within cells. The evolutionary 
scientifi c documents show that IL-12 cytokines β-subunits including p40 and 
Ebi3 have close relationship with IL-6R-α while a close homology is observed 
between gp130 and the both components of IL-12 receptors (IL-12R-β1 and 
 12R-β2), (Table I and Fig. 2). The gp130 molecule is present in receptors of 
 IL-27 (gp130 and WSX1) and IL-6 (gp130 and IL-6R-α). The glycoprotein of 
gp130, is the main signal transducer in association with IL-6 and IL-27 signalling 
pathways. Interestingly, the signalling pathway of IL-6 includes JAK1, JAK2, 
TYK2, STAT1, and STAT3. Moreover it is remarkable fi nding that, the IL-6 as 
well as IL-11 applies for gp130-gp130 homodimer-structures in its signalling 
pathway [31, 79, 94, 143, 144, 147, 148].
According to the previous studies, the 40-kDa molecule of p40 (IL-12-β-
subunit and IL-23-β-subunit) is able to build homodimer structures of (p40)2 
which have antagonistic functional properties against IL-12 and IL-23. The 
(p40)2 homodimers have a strong affi nity for IL-12R-β1-subunits. The new iden-
Table I. A structural comparison between IL-6 and IL-12 family cytokines
Cytokine 
family
Cytokines Structure α-Subunit β-Subunit
IL-6 cardiotrophin-1 (CT-1), 
cardiotrophin like cytokine (CLC), 
ciliary neurotrophic factor (CNTF), 
granulocyte colony stimulating factor 
(GCSF), IL-6, IL-11, 
leukaemia inhibitory factor (LIF), 
neuropoietin (NP), oncostatin M (OSM)
monomer Homologous to 
IL-12 cytokines 
α-subunits
No 
homology
IL-12 IL-12 heterodimer p35 p40
IL-23 p19 p40
IL-27 p28 Ebi3
IL-35 p35 Ebi3
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tifi ed homologies among IL-6 and IL-12 family members and the related recep-
tors have shown that, the gp130 as a receptor is able to contribute to inhibit the 
formation of (p40)2 homodimers through its high homology with IL-12R-β1 
and IL-12R-β2. Moreover, the IL-23 receptors include IL-12R-β1 and IL-23R; the 
IL-23R has a close similarity with gp130. These characteristics may decrease 
the formation of (p40)2 homodimers [31, 47, 141, 147, 149, 150].
Conclusion
Recent investigations reveal similarities and dissimilarities among func-
tions, structures, regulatory systems, and secretion pathways of IL-12 family 
members. The importance of IL-12 family is considerable in different fi elds such 
as gene therapy, cancer therapy, tumour therapy, and vaccination. Thus, the sci-
ence of bioengineering is trying to use IL-12 family members as especial thera-
peutic tools in modern pharmacology. Besides, the members of IL-12 family are 
known as important biomarkers in association with infections, autoimmune dis-
eases, and cancers.
Furthermore, the progression of advanced molecular diagnostic technology 
of microarray provides an appropriate opportunity for applying IL-12 family 
members as brilliant diagnostic playmakers in the fi eld of infectious diseases 
with high accuracy, reliability, and reproducibility.
The recent decade has given us the opportunity for identifying this group 
of cytokines. Identifi cation of cytokines, their receptors and signalling pathway 
permit us to have a much better diagnostic approach and designing defi nite ther-
apeutic methods. The results from different studies confi rm a variety of mecha-
nisms in different infections. So, an individual pathway and mechanism can be 
used as a prompt sign for performing an accurate diagnosis and defi nite treat-
ment. We conclude that, the ability of IL-12 family cytokines as signifi cant im-
munological playmakers together with microarray technology can provide us a 
new chapter of reliable diagnostics and successful treatments now and tomorrow.
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